NA
LKFT

NewEdge Advisors’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

NewEdge Advisors’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$180 Hold
6
– – ﹤0.01% 4122
2026
Q1 		$180 Hold
6
– – ﹤0.01% 4069
2025
Q4 		$196 Hold
6
– – ﹤0.01% 4133
2025
Q3 		$208 Hold
6
– – ﹤0.01% 4005
2025
Q2 		$168 Hold
6
– – ﹤0.01% 3884
2025
Q1 		$151 Hold
6
– – ﹤0.01% 3818
2024
Q4 		$165 Hold
6
– – ﹤0.01% 3754
2024
Q3 		$173 Sell
6
-8
-57% -$218 ﹤0.01% 3692
2024
Q2 		$347 Buy
14
+8
+133% +$227 ﹤0.01% 3613
2024
Q1 		$193 Hold
6
– – ﹤0.01% 3676
2023
Q4 		$244 Hold
6
– – ﹤0.01% 3590
2023
Q3 		$207 Hold
6
– – ﹤0.01% 3323
2023
Q2 		$244 Hold
6
– – ﹤0.01% 3370
2023
Q1 		$232 Hold
6
– – ﹤0.01% 3302
2022
Q4 		$0 Buy
+6
New +$252 ﹤0.01% 4124

Other funds holding LKFT

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
DCM
DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

NewEdge Advisors's LKFT Position: Q2 2026 in Review

NewEdge Advisors held its Lakefront Biotherapeutics American Depositary Shares (LKFT) position steady in Q2 2026 at 6 shares worth $180. The position accounts for ﹤0.01% of the portfolio, ranked #4122.

NewEdge Advisors first reported a position in LKFT in Q4 2022 and has held it in 15 quarters since. The position peaked at $347 in Q2 2024. 76 funds tracked by Wall St. Rank hold LKFT as of Q2 2026.

  • NewEdge Advisors held 6 shares of Lakefront Biotherapeutics American Depositary Shares worth $180 as of Q2 2026.
  • NewEdge Advisors left its Lakefront Biotherapeutics American Depositary Shares share count unchanged in Q2 2026.
  • Lakefront Biotherapeutics American Depositary Shares made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #4122 holding.
  • NewEdge Advisors first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q4 2022 and has held it in 15 quarters since.
  • NewEdge Advisors's Lakefront Biotherapeutics American Depositary Shares position peaked at $347 in Q2 2024.
  • 76 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.